Citadel Advisors’s Ingevity NGVT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $778K | Sell |
10,919
-21,534
| -66% | -$1.47M | ﹤0.01% | 8253 |
|
|
2025
Q4 | $1.92M | Sell |
32,453
-29,994
| -48% | -$1.63M | ﹤0.01% | 5997 |
|
|
2025
Q3 | $3.45M | Sell |
62,447
-12,328
| -16% | -$641K | ﹤0.01% | 5046 |
|
|
2025
Q2 | $3.22M | Buy |
74,775
+32,520
| +77% | +$1.25M | ﹤0.01% | 4861 |
|
|
2025
Q1 | $1.67M | Buy |
42,255
+32,819
| +348% | +$1.45M | ﹤0.01% | 5890 |
|
|
2024
Q4 | $385K | Sell |
9,436
-23,222
| -71% | -$967K | ﹤0.01% | 9141 |
|
|
2024
Q3 | $1.27M | Sell |
32,658
-60,575
| -65% | -$2.41M | ﹤0.01% | 6368 |
|
|
2024
Q2 | $4.08M | Sell |
93,233
-33,554
| -26% | -$1.62M | ﹤0.01% | 4068 |
|
|
2024
Q1 | $6.05M | Buy |
126,787
+106,910
| +538% | +$4.81M | ﹤0.01% | 3645 |
|
|
2023
Q4 | $939K | Sell |
19,877
-7,919
| -28% | -$329K | ﹤0.01% | 6798 |
|
|
2023
Q3 | $1.32M | Sell |
27,796
-21,344
| -43% | -$1.17M | ﹤0.01% | 6015 |
|
|
2023
Q2 | $2.86M | Buy |
49,140
+18,744
| +62% | +$1.12M | ﹤0.01% | 4553 |
|
|
2023
Q1 | $2.17M | Sell |
30,396
-13,641
| -31% | -$1.08M | ﹤0.01% | 5199 |
|
|
2022
Q4 | $3.1M | Sell |
44,037
-104,368
| -70% | -$7.36M | ﹤0.01% | 4701 |
|
|
2022
Q3 | $9M | Buy |
148,405
+26,354
| +22% | +$1.77M | ﹤0.01% | 2925 |
|
|
2022
Q2 | $7.71M | Buy |
122,051
+92,294
| +310% | +$6.01M | ﹤0.01% | 3033 |
|
|
2022
Q1 | $1.91M | Buy |
+29,757
| New | +$1.99M | ﹤0.01% | 6195 |
|
|
2021
Q4 | – | Sell |
-5,160
| Closed | -$392K | – | 14424 |
|
|
2021
Q3 | $368K | Buy |
+5,160
| New | +$407K | ﹤0.01% | 10594 |
|
|
2021
Q2 | – | Sell |
-15,950
| Closed | -$1.28M | – | 14147 |
|
|
2021
Q1 | $1.21M | Buy |
+15,950
| New | +$1.16M | ﹤0.01% | 7635 |
|
|
2020
Q4 | – | Sell |
-143,817
| Closed | -$9.37M | – | 11307 |
|
|
2020
Q3 | $7.11M | Sell |
143,817
-89,000
| -38% | -$5.02M | ﹤0.01% | 2681 |
|
|
2020
Q2 | $12.2M | Buy |
232,817
+28,350
| +14% | +$1.35M | ﹤0.01% | 1998 |
|
|
2020
Q1 | $7.2M | Buy |
204,467
+110,623
| +118% | +$6.46M | ﹤0.01% | 2249 |
|
|
2019
Q4 | $8.2M | Buy |
93,844
+7,495
| +9% | +$655K | ﹤0.01% | 2441 |
|
|
2019
Q3 | $7.33M | Buy |
86,349
+80,189
| +1,302% | +$7.14M | ﹤0.01% | 2606 |
|
|
2019
Q2 | $648K | Sell |
6,160
-84,816
| -93% | -$8.52M | ﹤0.01% | 6404 |
|
|
2019
Q1 | $9.61M | Buy |
+90,976
| New | +$9.14M | ﹤0.01% | 2129 |
|
|
2018
Q4 | – | Sell |
-3,669
| Closed | -$332K | – | 9553 |
|
|
2018
Q3 | $374K | Sell |
3,669
-1,067
| -23% | -$103K | ﹤0.01% | 7205 |
|
|
2018
Q2 | $383K | Buy |
+4,736
| New | +$376K | ﹤0.01% | 6805 |
|
|
2018
Q1 | – | Sell |
-33,737
| Closed | -$2.52M | – | 8605 |
|
|
2017
Q4 | $2.38M | Buy |
33,737
+18
| +0.1% | +$1.3K | ﹤0.01% | 3389 |
|
|
2017
Q3 | $2.11M | Buy |
33,719
+5,947
| +21% | +$352K | ﹤0.01% | 3352 |
|
|
2017
Q2 | $1.59M | Buy |
+27,772
| New | +$1.63M | ﹤0.01% | 3451 |
|
|
2016
Q3 | – | Sell |
-31,708
| Closed | -$1.08M | – | 7574 |
|
|
2016
Q2 | $1.08M | Buy |
+31,708
| New | +$990K | ﹤0.01% | 3457 |
|
Other funds holding NGVT
VPM
VCM
SBH
SCM
Citadel Advisors's NGVT Position: Q1 2026 in Review
Citadel Advisors reduced its Ingevity (NGVT) stake by 66% in Q1 2026, selling an estimated $1.47M and leaving 10,919 shares worth $778K. The position accounts for ﹤0.01% of the portfolio, ranked #8253.
Citadel Advisors first reported a position in NGVT in Q2 2016 and has held it in 32 quarters since. The position peaked at $12.2M in Q2 2020. 307 funds tracked by Wall St. Rank hold NGVT as of Q1 2026.
- Citadel Advisors held 10,919 shares of Ingevity worth $778K as of Q1 2026.
- Citadel Advisors sold 21,534 Ingevity shares in Q1 2026, an estimated $1.47M.
- Ingevity made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #8253 holding.
- Citadel Advisors first reported a position in Ingevity in Q2 2016 and has held it in 32 quarters since.
- Citadel Advisors's Ingevity position peaked at $12.2M in Q2 2020.
- 307 funds tracked by Wall St. Rank held Ingevity as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.